Navigation Links
Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
Date:6/25/2009

- Insmed to Evaluate Potential Initiation of Phase II Trial for IPLEX(TM) in MMD Patients with Severe Insulin Resistance -

RICHMOND, Va., June 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX(TM) (mecasermin rinfabate) in patients with myotonic muscular dystrophy ("MMD"). The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S. enrolled 69 patients with MMD, for a six-month period. As this was an exploratory trial, a primary endpoint was not pre-defined. The trial explored measures of endurance, using the six-minute walk test, muscle function and strength, cognitive function, gastrointestinal function, pain, quality of life, insulin sensitivity, lipid metabolism, and safety and tolerability of IPLEX(TM).

The results of the trial indicated that IPLEX(TM) did not exhibit a statistically significant improvement in the functional measure of endurance by the six-minute walk test, muscle function, muscle strength, or quality of life in any of the tests utilized in this study. Based on the limited number of subjects enrolled with significant impairments in cognitive function, gastrointestinal function or pain, Insmed was unable to reach any conclusions regarding the effects of IPLEX(TM) on these endpoints.

IPLEX(TM) did, however, demonstrate improvements in standard measures of insulin sensitivity and reductions in fasting glucose, fasting insulin, cholesterol and triglycerides, which is consistent with the expected metabolic profile of insulin-like growth factor. Administration of IPLEX(TM) also resulted in anabolic effects of increased body mass index and higher levels of testosterone. The drug was well tolerated in MMD subjects and d
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed CEO Resigns Due to Health Concerns
2. Insmed Announces First Quarter 2009 Financial Results
3. Insmed Regains NASDAQ Compliance
4. Insmed to Host First Quarter 2009 Conference Call
5. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
6. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
7. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
8. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
9. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
11. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... PALM BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/11/2014)... , Not for release, publication or ... any jurisdiction where to do so would constitute a violation ... plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... it has held a meeting with representatives of AbbVie. ... prior agreement or approval of AbbVie. A further ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... Industry Analysis, Size, Share, Growth, Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is a ... RNA) into cells. This technology helps the cells to ... metabolism by affecting the nuclear genes. The transfection technology ...
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3
... announced today that,it has signed an agreement with ... its proton therapy facility in Oklahoma City,Oklahoma. , ... ) , ".decimal ... with ProCure to be,their preferred outsource provider of ...
... CAMBRIDGE, Mass., Feb. 3 Abt Associates announced that ... Associate. After a brief orientation to the firm, ... education work in September 2009. Dr. Takai brings ... and management of federal evaluation studies in the field ...
... Than 75% of Biotech Firms Expect to Establish or ... Feb. 3 More biotechnology companies will be compelled ... more restrictive lending environment, according to "Plumbing the Depths," ... firm Rothstein Kass ( www.rkco.com ). Results were based ...
Cached Biology Technology:ProCure Signs Agreement with .decimal, Inc. to Purchase Patient-Specific Devices for Its Proton Therapy Center in Oklahoma City 2Dr. Ricky Takai, Expert in Designing and Managing Federal Evaluation Studies in Education, Joins Abt Associates 2Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 2Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 3Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 4
(Date:7/11/2014)... Wildlife Conservation Society shows that no-take zones in ... such as lobster, conch, and fish recover from ... areas. , The reporttitled "Review of the Benefits ... literature from no-take areas around the world. The ... recognized expert in marine protected areas and fisheries ...
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... were many fires burning in eastern New South Wales, ... 11. , At 03:35 UTC on July 11 (12:35 ... Aqua passed over eastern New South Wales (NSW), the ... visible image of the region and spotted smoke (light ... MODIS,s thermal bands, are outlined in red. , The ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... efforts may do it more for themselves than the ... Alberta case study shows. A study of purple ... their landrevealed that they were more motivated to take ... altruistic reasons. "Though there were areas of overlap, ...
... research to disease cure isn,t usually a smooth one. ... that of the "clinician-scientist" a doctor who understands disease ... Yet an editorial published in Disease Models & Mechanisms ... UK and elsewhere are not prospering, but rather are "under ...
... (IAH) are stepping up the battle against the devastating ... ways to trap and monitor midges with cutting edge ... gaining an understanding of how the insects spread the ... advise farmers how and when to protect their animals. ...
Cached Biology News:For the birds or for me? Why do conservationists really help wildlife? 2Medical doctors who do research could be a dying breed 2Midge-hunting scientists tackle spread of devastating bluetongue virus 2Midge-hunting scientists tackle spread of devastating bluetongue virus 3
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
prototype Nco I...
Biology Products: